PortfoliosLab logoPortfoliosLab logo
CURE vs. KORU
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

CURE vs. KORU - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Direxion Daily Healthcare Bull 3x Shares (CURE) and Direxion Daily MSCI South Korea Bull 3X Shares (KORU). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CURE achieves a 3.02% return, which is significantly lower than KORU's 139.37% return. Over the past 10 years, CURE has outperformed KORU with an annualized return of 13.07%, while KORU has yielded a comparatively lower 6.71% annualized return.


CURE

1D
1.84%
1M
22.58%
6M
2.43%
YTD
3.02%
1Y
60.79%
3Y*
3.52%
5Y*
1.07%
10Y*
13.07%
ALL TIME*
23.98%

KORU

1D
18.03%
1M
-60.16%
6M
64.51%
YTD
139.37%
1Y
406.75%
3Y*
65.37%
5Y*
3.37%
10Y*
6.71%
ALL TIME*
1.58%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CURE vs. KORU - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CURE
Direxion Daily Healthcare Bull 3x Shares
3.02%22.55%-8.47%-9.40%-20.51%88.30%5.02%55.66%2.82%69.32%
KORU
Direxion Daily MSCI South Korea Bull 3X Shares
139.37%432.73%-62.18%28.61%-70.16%-33.86%48.78%5.47%-59.89%167.08%

Correlation

The correlation between CURE and KORU is 0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.04

Correlation (3Y)
Calculated over the trailing 3-year period

0.20

Correlation (5Y)
Calculated over the trailing 5-year period

0.27

Correlation (10Y)
Calculated over the trailing 10-year period

0.36

Correlation (All Time)
Calculated using the full available price history since Apr 10, 2013

0.37

Over the past year, the correlation between CURE and KORU has dropped to 0.04 - well below their long-term average of 0.37, suggesting their price drivers have been diverging.

CURE vs. KORU - Sectors Allocation Comparison


Sectors
CURE
KORU

Healthcare

100.0%
3.1%

Basic Materials

-

1.2%

Communication Services

-

2.6%

Consumer Cyclical

-

4.7%

Consumer Defensive

-

1.7%

Energy

-

1.0%

Financial Services

-

8.8%

Industrials

-

15.4%

Real Estate

-

-

Technology

-

61.3%

Utilities

-

0.3%

Healthcare

CURE
100.0%
KORU
3.1%

Basic Materials

CURE

-

KORU
1.2%

Communication Services

CURE

-

KORU
2.6%

Consumer Cyclical

CURE

-

KORU
4.7%

Consumer Defensive

CURE

-

KORU
1.7%

Energy

CURE

-

KORU
1.0%

Financial Services

CURE

-

KORU
8.8%

Industrials

CURE

-

KORU
15.4%

Real Estate

CURE

-

KORU

-

Technology

CURE

-

KORU
61.3%

Utilities

CURE

-

KORU
0.3%

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CURE vs. KORU — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CURE
CURE Risk / Return Rank: 4848
Overall Rank
CURE Sharpe Ratio Rank: 5050
Sharpe Ratio Rank
CURE Sortino Ratio Rank: 5656
Sortino Ratio Rank
CURE Omega Ratio Rank: 4747
Omega Ratio Rank
CURE Calmar Ratio Rank: 5252
Calmar Ratio Rank
CURE Martin Ratio Rank: 3838
Martin Ratio Rank

KORU
KORU Risk / Return Rank: 9090
Overall Rank
KORU Sharpe Ratio Rank: 9494
Sharpe Ratio Rank
KORU Sortino Ratio Rank: 8181
Sortino Ratio Rank
KORU Omega Ratio Rank: 8686
Omega Ratio Rank
KORU Calmar Ratio Rank: 9595
Calmar Ratio Rank
KORU Martin Ratio Rank: 9191
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CURE vs. KORU - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Direxion Daily Healthcare Bull 3x Shares (CURE) and Direxion Daily MSCI South Korea Bull 3X Shares (KORU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CUREKORUDifference
Sharpe ratioReturn per unit of total volatility

-1.38

Sortino ratioReturn per unit of downside risk

-0.72

Omega ratioGain probability vs. loss probability

1.23

1.39

-0.16

Calmar ratioReturn relative to maximum drawdown

1.96

5.76

-3.80

Martin ratioReturn relative to average drawdown

4.37

15.72

-11.35

CURE vs. KORU - Sharpe Ratio Comparison

The current CURE Sharpe Ratio is 1.31, which is lower than the KORU Sharpe Ratio of 2.69. The chart below compares the historical Sharpe Ratios of CURE and KORU, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CURE vs. KORU - Drawdown Comparison

The maximum CURE drawdown since its inception was -69.19%, smaller than the maximum KORU drawdown of -95.79%. Use the drawdown chart below to compare losses from any high point for CURE and KORU.


Loading charts...

Drawdown Indicators


CUREKORUDifference

Max Drawdown

Largest peak-to-trough decline

-69.19%

-95.79%

+26.60%

Max Drawdown (1Y)

Largest decline over 1 year

-31.10%

-71.13%

+40.03%

Max Drawdown (3Y)

Largest decline over 3 years

-51.93%

-73.34%

+21.41%

Max Drawdown (5Y)

Largest decline over 5 years

-52.23%

-92.74%

+40.51%

Max Drawdown (10Y)

Largest decline over 10 years

-69.19%

-95.79%

+26.60%

Current Drawdown

Current decline from peak

-18.23%

-65.64%

+47.41%

Average Drawdown

Average peak-to-trough decline

-18.17%

-57.40%

+39.23%

Ulcer Index

Depth and duration of drawdowns from previous peaks

13.97%

26.04%

-12.07%

Volatility

CURE vs. KORU - Volatility Comparison

The current volatility for Direxion Daily Healthcare Bull 3x Shares (CURE) is 18.16%, while Direxion Daily MSCI South Korea Bull 3X Shares (KORU) has a volatility of 70.29%. This indicates that CURE experiences smaller price fluctuations and is considered to be less risky than KORU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CUREKORUDifference

Volatility (1M)

Calculated over the trailing 1-month period

18.16%

70.29%

-52.13%

Volatility (6M)

Calculated over the trailing 6-month period

34.67%

148.29%

-113.62%

Volatility (1Y)

Calculated over the trailing 1-year period

46.66%

152.54%

-105.88%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

44.53%

94.31%

-49.78%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

49.77%

84.57%

-34.80%

CURE vs. KORU - Expense Ratio Comparison

CURE has a 1.08% expense ratio, which is lower than KORU's 1.32% expense ratio.


Dividends

CURE vs. KORU - Dividend Comparison

CURE's dividend yield for the trailing twelve months is around 1.10%, more than KORU's 0.36% yield.


PositionTTM202520242023202220212020201920182017
CURE
Direxion Daily Healthcare Bull 3x Shares
1.10%1.12%1.17%2.02%0.38%0.02%0.17%0.40%0.70%0.18%
KORU
Direxion Daily MSCI South Korea Bull 3X Shares
0.36%0.89%4.10%2.55%0.48%0.76%0.01%0.93%1.40%3.59%

Frequently Asked Questions


CURE and KORU have a correlation of 0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

KORU has higher volatility (70.29%) compared to CURE (18.16%). In terms of maximum drawdown, CURE dropped -69.19% vs KORU's -95.79%.

On 10-year performance, CURE leads with 13.07% vs 6.71% for KORU. On fees, CURE is cheaper at 1.08% per year. On volatility, CURE has been the lower-risk option at 18.16%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 10-year period, CURE has performed better with a 13.07% return vs 6.71%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

CURE is cheaper with a 1.08% expense ratio, compared with 1.32% for KORU.

CURE has the higher dividend yield at 1.10%, compared with 0.36% for KORU.

CURE is categorized as Leveraged Equities, while KORU is South Korea Equities. CURE tracks Health Care Select Sector Index (300%), while KORU tracks MSCI Korea 25/50 Index. Their fees differ too: 1.08% for CURE and 1.32% for KORU.

KORU currently has the higher Sharpe Ratio (2.69 vs 1.31), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CURE and KORU

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer